Companies › Arrowhead Pharmaceuticals
9 active drug programs in 13 registered trials: 6 Phase 1, 6 Phase 3, 1 Phase 2; Metabolic and endocrine, Neurology, Ophthalmology, Respiratory; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zodasiran ANGPTL3 antisense oligonucleotide | ANGPTL3 | Phase 3 | Homozygous Familial Hypercholesterolemia | Aug 2027 |
| Plozasiran APOC3 antisense oligonucleotide | APOC3 | Phase 3 | Severe Hypertriglyceridemia; Hypertriglyceridemia | Jul 2028 |
| ARO-RAGE RAGE antagonist / inhibitor | AGER | Phase 2 | Asthma | Dec 2027 |
| ARO-ATXN2 Injection Antisense oligonucleotide targeting ATXN2 mRNA | ATXN2 | Phase 1 | Spinocerebellar Ataxia Type 2 | Dec 2026 |
| ARO-ALK7 ALK7 activator (activin receptor-like kinase 7 agonist) | ALK7 | Phase 1 | Obesity | Feb 2027 |
| ARO-MAPT-SC Antisense oligonucleotide targeting MAPT mRNA for reduction of tau protein | MAPT | Phase 1 | Alzheimer Disease | Jun 2027 |
| ARO-DIMERPA Antisense oligonucleotide (ASO) targeting apolipoprotein B mRNA | APOB | Phase 1 | Hyperlipidemia; Mixed | Jul 2027 |
| ARO-INHBE INHBE inhibitor (RNA interference) | INHBE | Phase 1 | Obesity | Oct 2027 |
| ARO-033 | – | Phase 1 | Age-related Macular Degeneration | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06347003 | Plozasiran | Phase 3 | Severe Hypertriglyceridemia | Metabolic and endocrine | Jun 2026 |
| NCT06347016 | Plozasiran | Phase 3 | Severe Hypertriglyceridemia | Metabolic and endocrine | Jun 2026 |
| NCT06672445 | ARO-ATXN2 Injection | Phase 1 | Spinocerebellar Ataxia Type 2 | Neurology | Dec 2026 |
| NCT06937203 | ARO-ALK7 | Phase 1 | Obesity | Metabolic and endocrine | Feb 2027 |
| NCT07221344 | ARO-MAPT-SC | Phase 1 | Alzheimer Disease | Neurology | Jun 2027 |
| NCT07223658 | ARO-DIMERPA | Phase 1 | Hyperlipidemia; Mixed | Metabolic and endocrine | Jul 2027 |
| NCT07037771 | Zodasiran | Phase 3 | Homozygous Familial Hypercholesterolemia | Metabolic and endocrine | Aug 2027 |
| NCT06700538 | ARO-INHBE | Phase 1 | Obesity | Metabolic and endocrine | Oct 2027 |
| NCT07241546 | ARO-RAGE | Phase 2 | Asthma | Respiratory | Dec 2027 |
| NCT07662096 | ARO-033 | Phase 1 | Age-related Macular Degeneration | Ophthalmology | Jul 2028 |
| NCT06822790 | Plozasiran | Phase 3 | Hypertriglyceridemia | Metabolic and endocrine | Jul 2028 |
| NCT07473843 | Zodasiran | Phase 3 | Homozygous Familial Hypercholesterolemia | Metabolic and endocrine | Jul 2028 |
| NCT06880770 | Plozasiran | Phase 3 | Severe Hypertriglyceridemia | Metabolic and endocrine | Mar 2029 |
Cash and short-term investments of $1.6bn on 2026-06-30; operating cash outflow about $107m a year; runway about 180 months at that burn, to Jun 2041; 5 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Amylyx Pharmaceuticals Ionis Pharmaceuticals Beijing Suncadia Pharmaceuticals BioMarin Pharmaceutical MBX Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.